News & Articles

Pharmaceutical News and Articles

Comprehensive and up-to-date drug news for both consumers and healthcare professionals.

Including medical news, pharmaceutical industry news, new drug approvals, applications and clinical trial results.

Daily MedNews

Here are some of the latest health and medical news developments, compiled by editors of HealthDay: Basketball Legend Abdul-Jabbar Treated for Leukemia Basketball great Kareem Abdul-Jabbar is being treated for chronic myeloid leukemia and has been...
(HealthDayNews) -- Here are the latest clinical trials, courtesy of ClinicalConnection.com: Psoriasis If you have moderate-to-severe plaque psoriasis, you may qualify for this study of an investigational medication. Participants will receive all...
TUESDAY, Nov. 10 -- Optical technology could help physicians detect small colorectal polyps during colonoscopies and save money, too, new research suggests. In the report, published online Nov. 10 in The Lancet Oncology, the study authors explained...
TUESDAY, Nov. 10 -- Methods to gauge blood cholesterol to determine vascular disease risk can be simplified, researchers in England say. Their method measures levels of either total or high-density lipoprotein (HDL, or "good" cholesterol) in the...
TUESDAY, Nov. 10 -- Even three years after finishing treatment for breast cancer, almost 50 percent of women report long-term pain, a new Danish study finds. The research, published in the Nov. 11 issue of the Journal of the American Medical...

More...

Pharma Industry News

Washington, D.C. (November 9, 2009) — Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Ken Johnson issued the following statement regarding the FDA’s Nov. 12-13 hearing (view testimony | view slide...
Audience: Anesthesiology and intensivist healthcare professionals, hospital risk managers ROCKVILLE, Md., Nov. 10, 2009-Hospira, Inc.and FDA notified healthcare professionals of the recall of 85 lots of Liposyn II 10%, Liposyn II 20%, Liposyn...
Electronic alerts persuade clinicians to switch from costly drugs to generic brands ROCHESTER, NY, November 09, 2009 - Simple computerized alerts can help curb the impulse to prescribe unnecessarily expensive, heavily marketed drugs, according to a...
ROCKVILLE, Md., Nov. 2, 2009--FDA notified healthcare professionals of revisions to the prescribing information for Byetta (exenatide) to include information on post-marketing reports of altered kidney function, including acute renal failure...
5min and HealthCentral Announce New Online Health Video Network Reaches Largest Health Audience Online; 5min as Exclusive Distribution Platform Enables Health Sites to Instantly Monetize Relevant Video Content ARLINGTON, VA AND NEW YORK (OCTOBER 28,...

More...

New Drug Approvals

PRINCETON, N.J.--(BUSINESS WIRE)--Nov 5, 2009 - Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has approved a labeling update for Reyataz to include long-term data from the CASTLE Study. The CASTLE...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 5, 2009 - Gloucester Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) approved Istodax (romidepsin) for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have...
ST. LOUIS & MISSISSAUGA, Ontario--(BUSINESS WIRE)--Nov 5, 2009 - Covidien, a leading global provider of healthcare products, and Nuvo Research Inc., a Canadian drug development company, today announced that the U.S. Food and Drug Administration...
SAN DIEGO and INDIANAPOLIS, Oct. 30, 2009 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for Byetta (exenatide)...
SILVER SPRING. Md., Oct. 26 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Arzerra (ofatumumab) for patients with chronic lymphocytic leukemia (CLL), a slowly progressing cancer of the blood and bone...

More...

New Drug Applications

MELBOURNE, Australia, and MENLO PARK, California U.S.A. (10 November 2009) – ChemGenex Pharmaceuticals Limited announced today that the U.S. Food & Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for Omapro...
Montreal, Canada – November 5, 2009 – Theratechnologies today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration ("FDA") will review Theratechnologies’ NDA for tesamorelin in...
BRISBANE, Calif., Nov. 4 /PRNewswire-FirstCall/ -- InterMune, Inc. today announced that it has submitted an electronic New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market pirfenidone for the...
CAMBRIDGE, Massachusetts, November 4/PRNewswire-FirstCall/ -- Shire plc, the global specialty biopharmaceutical company, today announced that the United States Food and Drug Administration (FDA) has granted Priority Review for the New Drug...
MEMPHIS, Tenn.--(BUSINESS WIRE)--Nov 2, 2009 - GTx, Inc. today announced that it has received a Complete Response Letter issued by the United States Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for toremifene 80 mg...

More...

Clinical Trials

WILMINGTON, Mass., Nov. 10 /PRNewswire/ -- The results of an independent investigator study just published in the online version of Dermatologic Surgery demonstrate that Levulan® Photodynamic Therapy (PDT) may reduce the rate of recurrence of...
LAVAL, QC, Nov. 10 /PRNewswire-FirstCall/ -- Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced an article has been published in the international journal of neuropsychiatric medicine, CNS Spectrums October, 2009 issue...
Schlieren (Zurich), Switzerland, November 10, 2009 – Cytos Biotechnology Ltd (SIX:CYTN) today gave an update on the development of its hypertension vaccine CYT006-AngQb. In a first phase IIa study (study 01) the vaccine was safe, well tolerated...
ALISO VIEJO, Calif., November 10, 2009 - AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced efficacy, safety and tolerability results from the 12-week open-label extension phase of the confirmatory Phase III STAR trial evaluating the...
Basel, 10 November, 2009 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today reports results from a 320 patient phase II proof-of-concept study with it’s investigational glycine transporter-1 inhibitor RG1678. The study showed that the compound...

More...

More News Resources


MedNotes
Advertisement

(web4)